Abciximab
Oxaprozin may increase the anticoagulant activities of Abciximab.
Abiraterone
The metabolism of Oxaprozin can be decreased when combined with Abiraterone.
Acebutolol
Oxaprozin may decrease the antihypertensive activities of Acebutolol.
Advertisement
Aceclofenac
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Aceclofenac.
Acemetacin
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Acemetacin.
Acenocoumarol
Oxaprozin may increase the anticoagulant activities of Acenocoumarol.
Advertisement
Acetaminophen
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Acetaminophen.
Acetyl Sulfisoxazole
The metabolism of Oxaprozin can be decreased when combined with Acetyl sulfisoxazole.
Adapalene
The risk or severity of adverse effects can be increased when Adapalene is combined with Oxaprozin.
Advertisement
Alclometasone
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Alclometasone.
Aldosterone
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Aldosterone.
Alendronate
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Alendronic acid.
Alendronic acid
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Alendronic acid.
Aliskiren
Oxaprozin may decrease the antihypertensive activities of Aliskiren.
Alminoprofen
The risk or severity of adverse effects can be increased when Alminoprofen is combined with Oxaprozin.
Alprenolol
Oxaprozin may decrease the antihypertensive activities of Alprenolol.
Alprostadil
The therapeutic efficacy of Alprostadil can be decreased when used in combination with Oxaprozin.
Amcinonide
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Amcinonide.
Amikacin
Oxaprozin may decrease the excretion rate of Amikacin which could result in a higher serum level.
Amiloride
Oxaprozin may decrease the antihypertensive activities of Amiloride.
Aminosalicylic Acid
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Aminosalicylic Acid.
Amiodarone
The metabolism of Oxaprozin can be decreased when combined with Amiodarone.
Ancrod
Oxaprozin may increase the anticoagulant activities of Ancrod.
Androstenedione
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Androstenedione.
Anhydrous Tacrolimus
Oxaprozin may increase the nephrotoxic activities of Tacrolimus.
Antipyrine
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Antipyrine.
Antithrombin III
Oxaprozin may increase the anticoagulant activities of Antithrombin III human.
Antithrombin III, Human
Oxaprozin may increase the anticoagulant activities of Antithrombin III human.
Apalutamide
The serum concentration of Oxaprozin can be decreased when it is combined with Apalutamide.
Apazone
The risk or severity of adverse effects can be increased when Azapropazone is combined with Oxaprozin.
Apixaban
Oxaprozin may increase the anticoagulant activities of Apixaban.
Apremilast
The risk or severity of adverse effects can be increased when Apremilast is combined with Oxaprozin.
Aprepitant
The metabolism of Oxaprozin can be increased when combined with Aprepitant.
Arbekacin
Oxaprozin may decrease the excretion rate of Arbekacin which could result in a higher serum level.
Ardeparin
Oxaprozin may increase the anticoagulant activities of Ardeparin.
Argatroban
Oxaprozin may increase the anticoagulant activities of Argatroban.
Argatroban Anhydrous
Oxaprozin may increase the anticoagulant activities of Argatroban.
Asenapine
Oxaprozin may decrease the antihypertensive activities of Asenapine.
Asian ginseng extract
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Ginseng.
Atenolol
Oxaprozin may decrease the antihypertensive activities of Atenolol.
Azelastine
The risk or severity of adverse effects can be increased when Azelastine is combined with Oxaprozin.
azficel-T
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Azficel-T.
Azilsartan
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Oxaprozin.
Azilsartan kamedoxomil
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Oxaprozin.
Azilsartan Medoxomil
The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Oxaprozin.
Azosemide
The therapeutic efficacy of Azosemide can be decreased when used in combination with Oxaprozin.
Balsalazide
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Balsalazide.
Bazedoxifene
Oxaprozin may increase the thrombogenic activities of Bazedoxifene.
Becaplermin
Oxaprozin may increase the anticoagulant activities of Becaplermin.
Beclomethasone Dipropionate
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Beclomethasone dipropionate.
Benazepril
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Benazepril.
Bendroflumethiazide
The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Oxaprozin.
Benzthiazide
The therapeutic efficacy of Benzthiazide can be decreased when used in combination with Oxaprozin.
Benzydamine
The risk or severity of adverse effects can be increased when Benzydamine is combined with Oxaprozin.
Betamethasone
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Betamethasone.
Betaxolol
Oxaprozin may decrease the antihypertensive activities of Betaxolol.
Betrixaban
The risk or severity of bleeding can be increased when Betrixaban is combined with Oxaprozin.
Bimatoprost
The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Oxaprozin.
Bisoprolol
Oxaprozin may decrease the antihypertensive activities of Bisoprolol.
Bivalirudin
Oxaprozin may increase the anticoagulant activities of Bivalirudin.
Bopindolol
Oxaprozin may decrease the antihypertensive activities of Bopindolol.
Bromfenac
The risk or severity of adverse effects can be increased when Bromfenac is combined with Oxaprozin.
Budesonide
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Budesonide.
Bufexamac
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Bufexamac.
Bumetanide
The therapeutic efficacy of Bumetanide can be decreased when used in combination with Oxaprozin.
Bupranolol
Oxaprozin may decrease the antihypertensive activities of Bupranolol.
Candesartan
The risk or severity of adverse effects can be increased when Candesartan is combined with Oxaprozin.
Candesartan Cilexetil
The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Oxaprozin.
Capecitabine
The metabolism of Oxaprozin can be decreased when combined with Capecitabine.
Capsaicin
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Capsaicin.
Captopril
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Captopril.
Carbamazepine
The metabolism of Oxaprozin can be increased when combined with Carbamazepine.
Carboprost
The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Oxaprozin.
Carboprost Tromethamine
The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Oxaprozin.
Carprofen
The risk or severity of adverse effects can be increased when Carprofen is combined with Oxaprozin.
Carteolol
Oxaprozin may decrease the antihypertensive activities of Carteolol.
Carvedilol
Oxaprozin may decrease the antihypertensive activities of Carvedilol.
Celecoxib
The risk or severity of adverse effects can be increased when Celecoxib is combined with Oxaprozin.
Celiprolol
Oxaprozin may decrease the antihypertensive activities of Celiprolol.
Ceritinib
The serum concentration of Oxaprozin can be increased when it is combined with Ceritinib.
Certoparin
Oxaprozin may increase the anticoagulant activities of Certoparin.
Chloroquine
The risk or severity of adverse effects can be increased when Chloroquine is combined with Oxaprozin.
Chlorothiazide
The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Oxaprozin.
Chlorotrianisene
Oxaprozin may increase the thrombogenic activities of Chlorotrianisene.
Chlorphenesin
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Chlorphenesin.
Chlorthalidone
The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Oxaprozin.
Cholecalciferol
The metabolism of Oxaprozin can be decreased when combined with Cholecalciferol.
Cholestyramine Resin
Cholestyramine can cause a decrease in the absorption of Oxaprozin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Choline Magnesium Trisalicyclate
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Choline magnesium trisalicylate.
Ciclesonide
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Ciclesonide.
Cilazapril
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Cilazapril.
Cinoxacin
Oxaprozin may increase the neuroexcitatory activities of Cinoxacin.
Ciprofloxacin
Oxaprozin may increase the neuroexcitatory activities of Ciprofloxacin.
Cisplatin
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Cisplatin.
Citalopram
Citalopram may increase the antiplatelet activities of Oxaprozin.
Citric Acid
Oxaprozin may increase the anticoagulant activities of Citric Acid.
Citric Acid, Anhydrous
Oxaprozin may increase the anticoagulant activities of Citric Acid.
Clobetasol
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Clobetasol.
Clobetasol Propionate
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Clobetasol propionate.
Clobetasone
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Clobetasone.
Clocortolone
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Clocortolone.
Clodronic Acid
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Clodronic Acid.
Clonixin
The risk or severity of adverse effects can be increased when Clonixin is combined with Oxaprozin.
Clotrimazole
The metabolism of Oxaprozin can be decreased when combined with Clotrimazole.
Colesevelam
Colesevelam can cause a decrease in the absorption of Oxaprozin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Colestipol
Colestipol can cause a decrease in the absorption of Oxaprozin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cortisone Acetate
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Cortisone acetate.
Crisaborole
The metabolism of Oxaprozin can be decreased when combined with Crisaborole.
Curcumin
The risk or severity of adverse effects can be increased when Curcumin is combined with Oxaprozin.
Cyclopenthiazide
The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Oxaprozin.
Cyclosporine
Oxaprozin may increase the nephrotoxic activities of Cyclosporine.
Dabigatran Etexilate
Oxaprozin may increase the anticoagulant activities of Dabigatran etexilate.
Dabrafenib
The serum concentration of Oxaprozin can be decreased when it is combined with Dabrafenib.
Dalteparin
Oxaprozin may increase the anticoagulant activities of Dalteparin.
Danaparoid
Oxaprozin may increase the anticoagulant activities of Danaparoid.
Deferasirox
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Deferasirox.
Deflazacort
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Deflazacort.
Delavirdine
The metabolism of Oxaprozin can be decreased when combined with Delavirdine.
Desipramine
Oxaprozin may decrease the antihypertensive activities of Desipramine.
Desirudin
Oxaprozin may increase the anticoagulant activities of Desirudin.
Desmopressin
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Desmopressin.
Desonide
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Desonide.
Desoximetasone
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Desoximetasone.
Desoxycorticosterone acetate
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Desoxycorticosterone acetate.
Desoxycorticosterone Pivalate
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Desoxycorticosterone Pivalate.
Desvenlafaxine
Desvenlafaxine may increase the antiplatelet activities of Oxaprozin.
Dexamethasone
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Dexamethasone.
Dexketoprofen
The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Oxaprozin.
Dextran
Oxaprozin may increase the anticoagulant activities of Dextran.
Diclofenac
The risk or severity of adverse effects can be increased when Diclofenac is combined with Oxaprozin.
Dicumarol
Oxaprozin may increase the anticoagulant activities of Dicoumarol.
Dienestrol
Oxaprozin may increase the thrombogenic activities of Dienestrol.
Diethylstilbestrol
Oxaprozin may increase the thrombogenic activities of Diethylstilbestrol.
Diflorasone
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Diflorasone.
Diflucortolone
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Difluocortolone.
Diflunisal
The risk or severity of adverse effects can be increased when Diflunisal is combined with Oxaprozin.
Difluprednate
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Difluprednate.
Digoxin
The serum concentration of Digoxin can be increased when it is combined with Oxaprozin.
Dihydrostreptomycin
Oxaprozin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.
Dinoprost
The therapeutic efficacy of Dinoprost can be decreased when used in combination with Oxaprozin.
Dinoprost Tromethamine
The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Oxaprozin.
Dinoprostone
The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Oxaprozin.
Dipyrone
The risk or severity of adverse effects can be increased when Metamizole is combined with Oxaprozin.
Dothiepin
The metabolism of Oxaprozin can be decreased when combined with Dosulepin.
Drospirenone
Oxaprozin may increase the hyperkalemic activities of Drospirenone.
Droxicam
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Droxicam.
Duloxetine
Duloxetine may increase the antiplatelet activities of Oxaprozin.
Edetic Acid
Oxaprozin may increase the anticoagulant activities of Edetic Acid.
Edoxaban
Oxaprozin may increase the anticoagulant activities of Edoxaban.
Efavirenz
The metabolism of Oxaprozin can be decreased when combined with Efavirenz.
Eicosapentaenoic Acid
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Icosapent.
Enalapril
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Enalapril.
Enalaprilat
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Enalaprilat.
Enalaprilat Anhydrous
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Enalaprilat.
Enoxacin
Oxaprozin may increase the neuroexcitatory activities of Enoxacin.
Enoxaparin
Oxaprozin may increase the anticoagulant activities of Enoxaparin.
Enoxaparin sodium
Oxaprozin may increase the anticoagulant activities of Enoxaparin.
Eplerenone
Oxaprozin may decrease the antihypertensive activities of Eplerenone.
Epoprostenol
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Oxaprozin.
Eprosartan
The risk or severity of adverse effects can be increased when Eprosartan is combined with Oxaprozin.
Equol, (-)-
Oxaprozin may increase the thrombogenic activities of Equol.
Escitalopram
Escitalopram may increase the antiplatelet activities of Oxaprozin.
Esmolol
Oxaprozin may decrease the antihypertensive activities of Esmolol.
Estradiol
Oxaprozin may increase the thrombogenic activities of Estradiol.
Estradiol acetate
Oxaprozin may increase the thrombogenic activities of Estradiol acetate.
Estradiol Cypionate
Oxaprozin may increase the thrombogenic activities of Estradiol cypionate.
Estradiol Valerate
Oxaprozin may increase the thrombogenic activities of Estradiol valerate.
Estriol
Oxaprozin may increase the thrombogenic activities of Estriol.
Estrogens, Conjugated (USP)
Oxaprozin may increase the thrombogenic activities of Conjugated estrogens.
Estrogens, Esterified (USP)
Oxaprozin may increase the thrombogenic activities of Estrogens, esterified.
Estrone
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Estrone.
Etanercept
The risk or severity of adverse effects can be increased when Etanercept is combined with Oxaprozin.
Ethacrynate
The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Oxaprozin.
Ethacrynic Acid
The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Oxaprozin.
Ethinyl Estradiol
Oxaprozin may increase the thrombogenic activities of Ethinyl Estradiol.
Ethylenediaminetetraacetate
Oxaprozin may increase the anticoagulant activities of Edetic Acid.
Etidronate
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Etidronic acid.
Etidronic Acid
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Etidronic acid.
Etodolac
The risk or severity of adverse effects can be increased when Etodolac is combined with Oxaprozin.
Etofenamate
The risk or severity of adverse effects can be increased when Etofenamate is combined with Oxaprozin.
Etoricoxib
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Etoricoxib.
Etravirine
The metabolism of Oxaprozin can be decreased when combined with Etravirine.
Evening primrose oil
The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Oxaprozin.
Felbinac
The risk or severity of adverse effects can be increased when Felbinac is combined with Oxaprozin.
Fenbufen
The risk or severity of adverse effects can be increased when Fenbufen is combined with Oxaprozin.
Fenoprofen
The risk or severity of adverse effects can be increased when Fenoprofen is combined with Oxaprozin.
Ferulic Acid
The risk or severity of adverse effects can be increased when Ferulic acid is combined with Oxaprozin.
Fish Oils
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Fish oil.
Fleroxacin
Oxaprozin may increase the neuroexcitatory activities of Fleroxacin.
Floctafenine
The risk or severity of adverse effects can be increased when Floctafenine is combined with Oxaprozin.
Floxuridine
The metabolism of Oxaprozin can be decreased when combined with Floxuridine.
Fluconazole
The metabolism of Oxaprozin can be decreased when combined with Fluconazole.
Fludrocortisone
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Fludrocortisone.
Fluindione
Oxaprozin may increase the anticoagulant activities of Fluindione.
Flumequine
Oxaprozin may increase the neuroexcitatory activities of Flumequine.
Flumethasone
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Flumethasone.
Flunisolide
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Flunisolide.
Flunisolide Anhydrous (obsolete)
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Flunisolide.
Fluocinolone Acetonide
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluocinolone Acetonide.
Fluocinonide
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluocinonide.
Fluocortolone
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluocortolone.
Fluorometholone
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluorometholone.
Fluorouracil
The metabolism of Oxaprozin can be decreased when combined with Fluorouracil.
Fluoxetine
Fluoxetine may increase the antiplatelet activities of Oxaprozin.
FLUPREDNIDENE
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluprednidene.
Fluprednisolone
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluprednisolone.
Flurandrenolide
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Flurandrenolide.
Flurbiprofen
The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Oxaprozin.
Fluticasone
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluticasone.
Fluticasone Furoate
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluticasone furoate.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Fluticasone propionate.
Fluvastatin
The metabolism of Oxaprozin can be decreased when combined with Fluvastatin.
Fluvoxamine
The metabolism of Oxaprozin can be decreased when combined with Fluvoxamine.
Folate
The therapeutic efficacy of Folic Acid can be decreased when used in combination with Oxaprozin.
Folic Acid
The therapeutic efficacy of Folic Acid can be decreased when used in combination with Oxaprozin.
Fondaparinux sodium
Oxaprozin may increase the anticoagulant activities of Fondaparinux sodium.
Formestane
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Formestane.
Fosinopril
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Fosinopril.
Fosphenytoin
The metabolism of Oxaprozin can be increased when combined with Fosphenytoin.
Framycetin
Oxaprozin may decrease the excretion rate of Framycetin which could result in a higher serum level.
Furosemide
The therapeutic efficacy of Furosemide can be decreased when used in combination with Oxaprozin.
Gatifloxacin
Oxaprozin may increase the neuroexcitatory activities of Gatifloxacin.
Gatifloxacin Anhydrous
Oxaprozin may increase the neuroexcitatory activities of Gatifloxacin.
Gemeprost
The therapeutic efficacy of Gemeprost can be decreased when used in combination with Oxaprozin.
Gemfibrozil
The metabolism of Oxaprozin can be decreased when combined with Gemfibrozil.
Gemifloxacin
Oxaprozin may increase the neuroexcitatory activities of Gemifloxacin.
Gemifloxacin Mesylate
Oxaprozin may increase the neuroexcitatory activities of Gemifloxacin.
Genistein
Oxaprozin may increase the thrombogenic activities of Genistein.
Gentamicin
Oxaprozin may decrease the excretion rate of Gentamicin which could result in a higher serum level.
Ginseng Preparation
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Ginseng.
Grepafloxacin
Oxaprozin may increase the neuroexcitatory activities of Grepafloxacin.
Halcinonide
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Halcinonide.
Halobetasol
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Ulobetasol.
Haloperidol
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Haloperidol.
Heparin
Oxaprozin may increase the anticoagulant activities of Heparin.
Hydralazine
Oxaprozin may decrease the antihypertensive activities of Hydralazine.
Hydrochlorothiazide
The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Oxaprozin.
Hydrocortisone
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Hydrocortisone.
Hydroflumethiazide
The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Oxaprozin.
Ibandronate
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Ibandronate.
Ibandronic Acid
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Ibandronate.
Ibuprofen
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Ibuprofen.
Icatibant
The risk or severity of adverse effects can be increased when Icatibant is combined with Oxaprozin.
Iloprost
The therapeutic efficacy of Iloprost can be decreased when used in combination with Oxaprozin.
Imidapril
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Imidapril.
Indapamide
The therapeutic efficacy of Indapamide can be decreased when used in combination with Oxaprozin.
Indinavir
The metabolism of Oxaprozin can be decreased when combined with Indinavir.
INDINAVIR ANHYDROUS
The metabolism of Oxaprozin can be decreased when combined with Indinavir.
Indobufen
The risk or severity of adverse effects can be increased when Indobufen is combined with Oxaprozin.
Indomethacin
The risk or severity of adverse effects can be increased when Indomethacin is combined with Oxaprozin.
Irbesartan
The metabolism of Oxaprozin can be decreased when combined with Irbesartan.
Kanamycin
Oxaprozin may decrease the excretion rate of Kanamycin which could result in a higher serum level.
kanamycin A
Oxaprozin may decrease the excretion rate of Kanamycin which could result in a higher serum level.
Kebuzone
The risk or severity of adverse effects can be increased when Kebuzone is combined with Oxaprozin.
Ketoconazole
The metabolism of Oxaprozin can be decreased when combined with Ketoconazole.
Ketoprofen
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Ketoprofen.
Ketorolac
The risk or severity of adverse effects can be increased when Ketorolac is combined with Oxaprozin.
Korean ginseng preparation
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Ginseng.
KOREAN GINSENG ROOT
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Ginseng.
Korean Ginseng Root Extract
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Ginseng.
Labetalol
Oxaprozin may decrease the antihypertensive activities of Labetalol.
Latanoprost
The therapeutic efficacy of Latanoprost can be decreased when used in combination with Oxaprozin.
Latanoprostene Bunod
The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Oxaprozin.
Leflunomide
The risk or severity of adverse effects can be increased when Leflunomide is combined with Oxaprozin.
Lepirudin
Oxaprozin may increase the anticoagulant activities of Lepirudin.
Levobetaxolol
Oxaprozin may decrease the antihypertensive activities of Levobetaxolol.
Levobunolol
Oxaprozin may decrease the antihypertensive activities of Levobunolol.
Levofloxacin
Oxaprozin may increase the neuroexcitatory activities of Levofloxacin.
Levofloxacin Anhydrous
Oxaprozin may increase the neuroexcitatory activities of Levofloxacin.
Levomilnacipran
Levomilnacipran may increase the antiplatelet activities of Oxaprozin.
Limonene, (+)-
The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Oxaprozin.
Lisinopril
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Lisinopril.
Lisinopril Anhydrous
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Lisinopril.
Lithium
The serum concentration of Lithium can be increased when it is combined with Oxaprozin.
Lithium Cation
The serum concentration of Lithium can be increased when it is combined with Oxaprozin.
Lomefloxacin
Oxaprozin may increase the neuroexcitatory activities of Lomefloxacin.
Lornoxicam
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Lornoxicam.
Losartan
The metabolism of Oxaprozin can be decreased when combined with Losartan.
Loteprednol
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Loteprednol.
Lovastatin
The metabolism of Oxaprozin can be decreased when combined with Lovastatin.
Loxoprofen
The risk or severity of adverse effects can be increased when Loxoprofen is combined with Oxaprozin.
Lubiprostone
The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Oxaprozin.
Lumacaftor
The serum concentration of Oxaprozin can be decreased when it is combined with Lumacaftor.
Magnesium Salicylate
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Magnesium salicylate.
Manidipine
The metabolism of Oxaprozin can be decreased when combined with Manidipine.
Masoprocol
The risk or severity of adverse effects can be increased when Masoprocol is combined with Oxaprozin.
Meclofenamate
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Oxaprozin.
Meclofenamic Acid
The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Oxaprozin.
Medronate
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Technetium Tc-99m medronate.
Medrysone
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Medrysone.
Mefenamic Acid
The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Oxaprozin.
Meloxicam
The risk or severity of adverse effects can be increased when Meloxicam is combined with Oxaprozin.
Mepindolol
Oxaprozin may decrease the antihypertensive activities of Mepindolol.
Mesalamine
The risk or severity of adverse effects can be increased when Mesalazine is combined with Oxaprozin.
Mestranol
Oxaprozin may increase the thrombogenic activities of Mestranol.
Methotrexate
The serum concentration of Methotrexate can be increased when it is combined with Oxaprozin.
Methyclothiazide
The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Oxaprozin.
Methylprednisolone
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Methylprednisolone.
Metipranolol
Oxaprozin may decrease the antihypertensive activities of Metipranolol.
Metolazone
The therapeutic efficacy of Metolazone can be decreased when used in combination with Oxaprozin.
Metoprolol
Oxaprozin may decrease the antihypertensive activities of Metoprolol.
Midostaurin
The metabolism of Oxaprozin can be decreased when combined with Midostaurin.
Mifepristone
The serum concentration of Oxaprozin can be increased when it is combined with Mifepristone.
Milnacipran
Milnacipran may increase the antiplatelet activities of Oxaprozin.
Misoprostol
The therapeutic efficacy of Misoprostol can be decreased when used in combination with Oxaprozin.
Moexipril
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Moexipril.
Mometasone
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Mometasone.
Morniflumate
The risk or severity of adverse effects can be increased when Morniflumate is combined with Oxaprozin.
Moxifloxacin
Oxaprozin may increase the neuroexcitatory activities of Moxifloxacin.
MYCOPHENOLATE
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Oxaprozin.
Mycophenolate Mofetil
The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Oxaprozin.
Mycophenolic Acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Oxaprozin.
Nabilone
The metabolism of Oxaprozin can be decreased when combined with Nabilone.
Nabumetone
The risk or severity of adverse effects can be increased when Nabumetone is combined with Oxaprozin.
Nadolol
Oxaprozin may decrease the antihypertensive activities of Nadolol.
Nadroparin
Oxaprozin may increase the anticoagulant activities of Nadroparin.
Naftifine
The risk or severity of adverse effects can be increased when Naftifine is combined with Oxaprozin.
Nalidixic Acid
Oxaprozin may increase the neuroexcitatory activities of Nalidixic Acid.
Naproxen
The risk or severity of adverse effects can be increased when Naproxen is combined with Oxaprozin.
Nebivolol
Oxaprozin may decrease the antihypertensive activities of Nebivolol.
Nefazodone
Nefazodone may increase the antiplatelet activities of Oxaprozin.
Neomycin
Oxaprozin may decrease the excretion rate of Neomycin which could result in a higher serum level.
Nepafenac
The risk or severity of adverse effects can be increased when Nepafenac is combined with Oxaprozin.
Netilmicin
Oxaprozin may decrease the excretion rate of Netilmicin which could result in a higher serum level.
Nicardipine
The metabolism of Oxaprozin can be decreased when combined with Nicardipine.
Niflumic Acid
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Niflumic Acid.
Nimesulide
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Nimesulide.
Norfloxacin
Oxaprozin may increase the neuroexcitatory activities of Norfloxacin.
Oenothera biennis seed extract
The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Oxaprozin.
Ofloxacin
Oxaprozin may increase the neuroexcitatory activities of Ofloxacin.
Olmesartan
The risk or severity of adverse effects can be increased when Olmesartan is combined with Oxaprozin.
Olopatadine
The risk or severity of adverse effects can be increased when Olopatadine is combined with Oxaprozin.
Olsalazine
The risk or severity of adverse effects can be increased when Olsalazine is combined with Oxaprozin.
Omacetaxine Mepesuccinate
The risk or severity of bleeding can be increased when Oxaprozin is combined with Omacetaxine mepesuccinate.
Omeprazole
The metabolism of Oxaprozin can be decreased when combined with Omeprazole.
Oxprenolol
Oxaprozin may decrease the antihypertensive activities of Oxprenolol.
Oxyphenbutazone
The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Oxaprozin.
Palmidrol
The risk or severity of adverse effects can be increased when Palmidrol is combined with Oxaprozin.
Pamidronate
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Pamidronate.
Pamidronic Acid
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Pamidronate.
Paramethasone
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Paramethasone.
Parecoxib
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Parecoxib.
Paromomycin
Oxaprozin may decrease the excretion rate of Paromomycin which could result in a higher serum level.
Paroxetine
Paroxetine may increase the antiplatelet activities of Oxaprozin.
Parthenolide
The risk or severity of adverse effects can be increased when Parthenolide is combined with Oxaprozin.
Pefloxacin
Oxaprozin may increase the neuroexcitatory activities of Pefloxacin.
Penbutolol
Oxaprozin may decrease the antihypertensive activities of Penbutolol.
Pentaerythritol Tetranitrate
Oxaprozin may increase the anticoagulant activities of Pentaerythritol Tetranitrate.
Pentosan Polysulfate
Oxaprozin may increase the anticoagulant activities of Pentosan Polysulfate.
Perindopril
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Perindopril.
Phenindione
Oxaprozin may increase the anticoagulant activities of Phenindione.
Phenobarbital
The metabolism of Oxaprozin can be increased when combined with Phenobarbital.
Phenprocoumon
Oxaprozin may increase the anticoagulant activities of Phenprocoumon.
Phenylbutazone
The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Oxaprozin.
Phenytoin
The metabolism of Oxaprozin can be increased when combined with Phenytoin.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Oxaprozin.
Pindolol
Oxaprozin may decrease the antihypertensive activities of Pindolol.
Piretanide
The therapeutic efficacy of Piretanide can be decreased when used in combination with Oxaprozin.
Pirfenidone
The risk or severity of adverse effects can be increased when Pirfenidone is combined with Oxaprozin.
Piroxicam
The risk or severity of adverse effects can be increased when Piroxicam is combined with Oxaprozin.
Piroxicam-Beta-Cyclodextrin
The risk or severity of adverse effects can be increased when Piroxicam is combined with Oxaprozin.
Plazomicin
Oxaprozin may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Polyestradiol Phosphate
Oxaprozin may increase the thrombogenic activities of Polyestradiol phosphate.
Polythiazide
The therapeutic efficacy of Polythiazide can be decreased when used in combination with Oxaprozin.
Pomalidomide
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Pomalidomide.
Potassium Citrate
Oxaprozin may increase the anticoagulant activities of Potassium Citrate.
Practolol
Oxaprozin may decrease the antihypertensive activities of Practolol.
Pralatrexate
The serum concentration of Pralatrexate can be increased when it is combined with Oxaprozin.
Prasterone
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Prasterone.
Prednicarbate
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Prednicarbate.
Prednisolone
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Prednisolone.
Prednisone
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Prednisone.
Pregnenolone
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Pregnenolone.
Primidone
The metabolism of Oxaprozin can be increased when combined with Primidone.
Probenecid
The serum concentration of Oxaprozin can be increased when it is combined with Probenecid.
Promestriene
Oxaprozin may increase the thrombogenic activities of Promestriene.
Propafenone
Oxaprozin may decrease the antihypertensive activities of Propafenone.
Propranolol
Oxaprozin may decrease the antihypertensive activities of Propranolol.
protein C, human
Oxaprozin may increase the anticoagulant activities of Protein C.
protein S, human
Oxaprozin may increase the anticoagulant activities of Protein S human.
Protocatechualdehyde
Oxaprozin may increase the anticoagulant activities of Protocatechualdehyde.
Pyrimethamine
The metabolism of Oxaprozin can be decreased when combined with Pyrimethamine.
Quinapril
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Quinapril.
Quinestrol
Oxaprozin may increase the thrombogenic activities of Quinestrol.
Quinethazone
The therapeutic efficacy of Quinethazone can be decreased when used in combination with Oxaprozin.
Quinine
The metabolism of Oxaprozin can be decreased when combined with Quinine.
Ramipril
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Ramipril.
Rescinnamine
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Rescinnamine.
Resveratrol
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Resveratrol.
Reviparin
Oxaprozin may increase the anticoagulant activities of Reviparin.
Reviparin sodium
Oxaprozin may increase the anticoagulant activities of Reviparin.
Rifampin
The metabolism of Oxaprozin can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Oxaprozin can be increased when combined with Rifapentine.
Rimexolone
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Rimexolone.
Risedronate
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Risedronate.
Risedronic Acid
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Risedronate.
Rivaroxaban
Oxaprozin may increase the anticoagulant activities of Rivaroxaban.
Rofecoxib
The risk or severity of adverse effects can be increased when Rofecoxib is combined with Oxaprozin.
Rosoxacin
Oxaprozin may increase the neuroexcitatory activities of Rosoxacin.
Rucaparib
The metabolism of Oxaprozin can be decreased when combined with Rucaparib.
Sacubitril
The risk or severity of adverse effects can be increased when Sacubitril is combined with Oxaprozin.
Salicylamide
The risk or severity of adverse effects can be increased when Salicylamide is combined with Oxaprozin.
Salicylic Acid
The risk or severity of adverse effects can be increased when Salicylic acid is combined with Oxaprozin.
Salsalate
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Salsalate.
Saralasin
The risk or severity of adverse effects can be increased when Saralasin is combined with Oxaprozin.
Sarilumab
Sarilumab may increase the immunosuppressive activities of Oxaprozin.
Secobarbital
The metabolism of Oxaprozin can be increased when combined with Secobarbital.
Serratiopeptidase
The risk or severity of adverse effects can be increased when Serrapeptase is combined with Oxaprozin.
Sertraline
Sertraline may increase the antiplatelet activities of Oxaprozin.
Sildenafil
The metabolism of Oxaprozin can be decreased when combined with Sildenafil.
Sisomicin
Oxaprozin may decrease the excretion rate of Sisomicin which could result in a higher serum level.
Sodium Citrate
Oxaprozin may increase the anticoagulant activities of Sodium Citrate.
Sodium Phosphate
Sodium phosphate may increase the nephrotoxic activities of Oxaprozin.
Sodium Phosphate, Monobasic
Sodium phosphate may increase the nephrotoxic activities of Oxaprozin.
SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
Sodium phosphate may increase the nephrotoxic activities of Oxaprozin.
Sorafenib
The metabolism of Oxaprozin can be decreased when combined with Sorafenib.
Sotalol
Oxaprozin may decrease the antihypertensive activities of Sotalol.
Sparfloxacin
Oxaprozin may increase the neuroexcitatory activities of Sparfloxacin.
Spirapril
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Spirapril.
Spironolactone
Oxaprozin may decrease the antihypertensive activities of Spironolactone.
Streptomycin
Oxaprozin may decrease the excretion rate of Streptomycin which could result in a higher serum level.
Sulfadiazine
The metabolism of Oxaprozin can be decreased when combined with Sulfadiazine.
Sulfamethoxazole
The metabolism of Oxaprozin can be decreased when combined with Sulfamethoxazole.
Sulfasalazine
The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Oxaprozin.
Sulfisoxazole
The metabolism of Oxaprozin can be decreased when combined with Sulfisoxazole.
Sulindac
The risk or severity of adverse effects can be increased when Sulindac is combined with Oxaprozin.
Suprofen
The risk or severity of adverse effects can be increased when Suprofen is combined with Oxaprozin.
synthetic conjugated estrogens, A
Oxaprozin may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.
synthetic conjugated estrogens, B
Oxaprozin may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.
Tacrolimus
Oxaprozin may increase the nephrotoxic activities of Tacrolimus.
Tafluprost
The therapeutic efficacy of Tafluprost can be decreased when used in combination with Oxaprozin.
Talinolol
Oxaprozin may decrease the antihypertensive activities of Talinolol.
Talniflumate
The risk or severity of adverse effects can be increased when Talniflumate is combined with Oxaprozin.
Technetium Tc 99m Medronate
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Technetium Tc-99m medronate.
Telmisartan
The risk or severity of adverse effects can be increased when Telmisartan is combined with Oxaprozin.
Temafloxacin
Oxaprozin may increase the neuroexcitatory activities of Temafloxacin.
Tenofovir Disoproxil
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Tenofovir disoproxil.
Tenoxicam
The risk or severity of adverse effects can be increased when Tenoxicam is combined with Oxaprozin.
Terbutaline
Oxaprozin may decrease the antihypertensive activities of Terbutaline.
Terbutaline Sulfate
Oxaprozin may decrease the antihypertensive activities of Terbutaline.
Teriflunomide
The risk or severity of adverse effects can be increased when Teriflunomide is combined with Oxaprozin.
Tertatolol
Oxaprozin may decrease the antihypertensive activities of Tertatolol.
Tiaprofenic Acid
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Tiaprofenic acid.
Tibolone
Oxaprozin may increase the thrombogenic activities of Tibolone.
Ticagrelor
The metabolism of Oxaprozin can be decreased when combined with Ticagrelor.
Ticlopidine
The metabolism of Oxaprozin can be decreased when combined with Ticlopidine.
Tiludronate
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Tiludronic acid.
Tiludronic Acid
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Tiludronic acid.
Timolol
Oxaprozin may decrease the antihypertensive activities of Timolol.
Timolol Anhydrous
Oxaprozin may decrease the antihypertensive activities of Timolol.
Tixocortol
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Tixocortol.
Tobramycin
Oxaprozin may decrease the excretion rate of Tobramycin which could result in a higher serum level.
Tolbutamide
The metabolism of Oxaprozin can be decreased when combined with Tolbutamide.
Tolfenamic Acid
The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Oxaprozin.
Tolmetin
The risk or severity of adverse effects can be increased when Tolmetin is combined with Oxaprozin.
Torsemide
The therapeutic efficacy of Torasemide can be decreased when used in combination with Oxaprozin.
Trandolapril
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Trandolapril.
Tranilast
The risk or severity of adverse effects can be increased when Tranilast is combined with Oxaprozin.
Travoprost
The therapeutic efficacy of Travoprost can be decreased when used in combination with Oxaprozin.
Treprostinil
The risk or severity of adverse effects can be increased when Treprostinil is combined with Oxaprozin.
Triamcinolone
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Triamcinolone.
Triamterene
Oxaprozin may decrease the antihypertensive activities of Triamterene.
Tribenoside
The risk or severity of adverse effects can be increased when Tribenoside is combined with Oxaprozin.
Trichlormethiazide
The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Oxaprozin.
Trimethoprim
The metabolism of Oxaprozin can be decreased when combined with Trimethoprim.
Trisodium Citrate Anhydrous
Oxaprozin may increase the anticoagulant activities of Sodium Citrate.
Trolamine Salicylate
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Trolamine salicylate.
Trovafloxacin
Oxaprozin may increase the neuroexcitatory activities of Trovafloxacin.
Troxerutin
Oxaprozin may increase the anticoagulant activities of Troxerutin.
UNOPROSTONE
The therapeutic efficacy of Unoprostone can be decreased when used in combination with Oxaprozin.
Valdecoxib
The risk or severity of adverse effects can be increased when Valdecoxib is combined with Oxaprozin.
Valproate
The metabolism of Oxaprozin can be decreased when combined with Valproic Acid.
Valproic Acid
The metabolism of Oxaprozin can be decreased when combined with Valproic Acid.
Valsartan
The metabolism of Oxaprozin can be decreased when combined with Valsartan.
Vancomycin
The serum concentration of Vancomycin can be increased when it is combined with Oxaprozin.
Venlafaxine
Venlafaxine may increase the antiplatelet activities of Oxaprozin.
Voriconazole
The metabolism of Oxaprozin can be decreased when combined with Voriconazole.
Warfarin
Oxaprozin may increase the anticoagulant activities of Warfarin.
Zafirlukast
The metabolism of Oxaprozin can be decreased when combined with Zafirlukast.
Zileuton
The risk or severity of adverse effects can be increased when Zileuton is combined with Oxaprozin.
Zofenopril
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Zofenopril.
Zoledronic Acid
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Zoledronic acid.
Zoledronic Acid Anhydrous
The risk or severity of adverse effects can be increased when Oxaprozin is combined with Zoledronic acid.
Zomepirac
The risk or severity of adverse effects can be increased when Zomepirac is combined with Oxaprozin.
